The Digital Therapeutics Evidence Gap: What FDA Authorization Actually Required
Dr. Dereck Mush, MD, MBA
Strand Therapeutics
Clinical-stage biotechnology company developing programmable mRNA therapies.
What they do
Strand Therapeutics describes itself as a Boston-based clinical-stage biotechnology company developing programmable mRNA medicines for cancer and autoimmune disease. The Galien Foundation named it Best Startup in Biotechnology at the 2026 Prix Galien USA awards, announced October 30. The award is not a drug approval.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Programmable mRNA
- Product type
- Platform software
- Stage
- Growth
- Headquarters
- Boston, USA
- Region
- North America
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
The Skull as Therapeutic Infrastructure: How CraniUS and Chronic Convection Delivery Bypass the Blood-Brain Barrier
Dr. Dereck Mush, MD, MBA
State Medicaid programmes are quietly becoming a testing ground for digital therapeutics coverage
Dr. Dereck Mush, MD, MBA